Outcome of Breast Cancer in Moroccan Young Women Correlated to Clinic-Pathological Features, Risk Factors and Treatment: A Comparative Study of 716 Cases in a Single Institution

• Published in: PloS one 2016-10, Vol.11 (10), p.e0164841-e0164841
• Main Authors: Slaoui, Meriem, Mouh, Fatima Zahra, Ghanname, Imane, Razine, Rachid, El Mzibri, Mohammed, Amrani, Mariam
• Format: Article
• Language: English
• Subjects: Adult; Age; Biology and Life Sciences; Biomarkers; Biomarkers, Tumor - metabolism; Breast cancer; Breast Neoplasms - epidemiology; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Cancer; Cancer patients; Cancer research; Cancer therapies; Chemotherapy; Comparative analysis; Comparative studies; Contraceptives, Oral - pharmacology; Development and progression; Disease-Free Survival; Epidemiology; Family medical history; Female; Gene Expression Regulation, Neoplastic; Genetic analysis; Health risk assessment; Health risks; Humans; Inflammation; Medical diagnosis; Medical prognosis; Medical research; Medicine; Medicine and Health Sciences; Metastases; Metastasis; Middle Aged; Morocco - epidemiology; Multivariate analysis; Neoplasm Metastasis; Obesity; Obesity - complications; Oncology; Patient outcomes; Patients; Pharmacy; Progesterone; Prognosis; Radiation therapy; Radiotherapy; Recurrence; Reproductive status; Retrospective Studies; Risk analysis; Risk Factors; Statistical analysis; Survival; Tumors; Womens health; Young women
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0164841

Breast cancer in young women is quite uncommon and shows more aggressive characteristics with major disparities between worldwide populations. Prognosis and outcome of breast cancer in young patients are widely studied, but still no consensus is available. We retrospectively included 716 cases of breast cancer women diagnosed in 2009 at the National Institute of Oncology of Rabat. Patients were divided into two groups according to their age: women aged ≤40 years (Group 1) and women aged >40 years (Group 2). Data were recorded from patients' medical files and analyzed using SPSS 13.0 software (IBM). Young patients represent 24.9% of all patients with breast cancer. The comparison between the two groups displayed significant differences regarding nulliparity (p = 0.001) and progesterone receptor negativity (p = 0.01). Moreover, more progression (Metastases/Relapse) was registered in young women as compared to older women with breast cancer (p = 0.03). The estimated median follow-up period was 31 months. The 5-years Event-Free Survival (EFS) of patients with local disease was 64.6% in young women and 71.5% in older women with breast cancer (p = 0.04). Multivariate analysis in young women showed that nulliparity (HR: 7.2; 95%CI: 1.16-44.54; p = 0.03), T3 tumors (HR: 17.39; 95%CI: 1.74-173.34; p = 0.01) and negative PgR status (HR: 19.85; 95%CI: 1.07-366.54; p = 0.04) can be considered as risk factors for poorer event free survival while hormone therapy was associated with better EFS (HR: 0.11; 95%CI: 0.00-0.75; p = 0.03). In Group 2, multivariate analysis showed that patients with inflammatory breast cancer, N+ status, absence of radiotherapy, absence of chemotherapy, and absence of hormone therapy are at increased risk of recurrence. In Morocco, breast cancer is more frequent in young women as compared to western countries. Breast cancer in young women is more aggressive and is diagnosed late, leading to an intensive treatment. Moreover, the main factors associated with breast cancer development in young women would be hormonal and reproductive status. Analysis of other genetic biomarkers is needed to explain the high prevalence of breast cancer in young women to improve breast cancer management in Morocco.